Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06646627 · ClinicalTrials.gov registry record · Phase 1

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

A Phase 1 study of Ovarian Cancer, sponsored by Stanford University.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
1
Study location

NCT06646627 is a Phase 1 study of Ovarian Cancer that is actively recruiting participants, run by Stanford University. The registered enrollment target is 48 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06646627, a Phase 1 study of Ovarian Cancer, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

Conditions Studied

Ovarian Cancer

Interventions

  • DRUG B7-H3CART

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2024-11-11
Est. Completion 2026-07
Phase Phase 1

Sponsor

Stanford University

1,744 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06646627

The ClinicalTrials.gov registry entry for NCT06646627 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which B7-H3CART is the first listed.

NCT06646627 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06646627 about?

NCT06646627 is a clinical study titled "Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors". This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

What is the current status of trial NCT06646627?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-11-11. Estimated completion is 2026-07.

What conditions does trial NCT06646627 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT06646627?

The interventions under investigation include: B7-H3CART (DRUG).

Who is sponsoring clinical trial NCT06646627?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06646627 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.